|
Synonyms: TQJ-230 | TQJ230
Compound class:
Nucleic acid
Comment: Pelacarsen (TQJ230) is an apolipoprotein A synthesis reducer. It is a liver-targeted antisense oligonucleotide that was designed to lower serum lipoprotein A as a mechanism to reduce atherosclerotic cardiovascular disease risk [1-2].
We have been unable to locate a full chemical SMILES for the drug, or its HELM notation. We provide the basic nucleic acid structure for the molecule here. Full specifications for all modifications are available from its INN record. |
| No information available. |
Summary of Clinical Use  |
| Novartis are carrying out clinical trials to determine the safety and efficacy of pelacarsen (TQJ230). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06267560 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD | Phase 3 Interventional | Novartis | ||
| NCT05900141 | An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 Interventional | Novartis | ||
| NCT05305664 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany | Phase 3 Interventional | Novartis | ||
| NCT04023552 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Phase 3 Interventional | Novartis | ||
